You are currently browsing the archives for the New Tests category.

Archives

Archive for the 'New Tests' Category

Molecular Pathology Laboratory Network, Inc. (MPLN) now offers K-RAS mutation testing to assist with the identification of colorectal cancer (CRC) patients most likely to show limited clinical response to anti-epidermal growth factor receptor (anti-EGFR) therapies. Read the rest of this entry »

April 25, 2008

Human papillomavirus (HPV) genotyping is now offered by Molecular Pathology Laboratory Network, Inc. (MPLN). Read the rest of this entry »

Molecular Pathology Laboratory Network, Inc. (MPLN) continues to expand its oncology test menu with an additional application of the CellSearch System now available to monitor circulating tumor cells (CTCs) in patients with metastatic prostate cancer. CellSearch is also used to monitor CTCs in metastatic breast and metastatic colon cancers.
CellSearch is an advanced diagnostic platform commercially available from Veridex, LLC that enables the capture, identification and classification of rare CTCs in the blood stream that detach from solid tumors. Read the rest of this entry »

December 20, 2007

Patients taking the drug warfarin may benefit from a new FDA-approved assay that detects variations in the two specific genes that influence a patient’s response to the drug. Read the rest of this entry »

Molecular Pathology Laboratory Network, Inc. (MPLN) in Maryville, Tenn. expands its oncology test menu as one of the first regional reference laboratories in the Southeast to offer CellSearch™ for monitoring circulating tumor cells (CTCs) in metastatic colorectal cancer. Read the rest of this entry »

November 20, 2007

In early 2008, Molecular Pathology Laboratory Network, Inc. (MPLN) will offer three new innovative tests to help physicians manage and treat their patients even better. Read the rest of this entry »

MPLN Now Offers FLT3

Author: sveiga
May 15, 2007

MPLN now offers FLT3 testing as a prognostic indicator in acute myeloid leukemia (AML).

FLT3 Test Page

The Ph negative subsets in CMPD (PV, ET, CIMF) are more challenging to diagnose and require close correlation with Read the rest of this entry »

January 1, 2007

UGT1A1 Is a one-time screening test Read the rest of this entry »